RUNX2 and acute myeloid leukemia: The aforementioned led us to conduct phosphoproteomics analysis of HL-60 and OCI-AML3 cells treated with the peptide in order to fully gauge the complexity of the CIGB-300 inhibitory mechanism in AML cells (Figure 5B).